11-Hydroxy-Androsterone (OHAN) is a urinary metabolite of cortisol metabolism as well as 11-oxygenated androgens production from the adrenal glands. While research is limited in the significance of elevations of this metabolite, it may be associated with certain conditions like 21-hydroxylase deficiency and castration- resistant prostate cancer.

11-Hydroxy-etiocholanolone is a compound that is an end product of androgen catabolism.

Androgens are important hormones in the health of both men and women. Testosterone and DHEA are metabolized into what is collectively known as the 17-ketosteroids (DHEA is formally included as a 17-ketosteroid). Together, these markers provide a comprehensive assessment of androgen sufficiency, as well as evaluating the need for, and monitoring of, androgen hormone therapy.

11-Hydroxy-etiocholanolone is a compound that is an end product of androgen catabolism.

Androgens are important hormones in the health of both men and women. Testosterone and DHEA are metabolized into what is collectively known as the 17-ketosteroids (DHEA is formally included as a 17-ketosteroid). Together, these markers provide a comprehensive assessment of androgen sufficiency, as well as evaluating the need for, and monitoring of, androgen hormone therapy.

AspirinWorks® 11-Dehydrothromboxane B2 (11-dhTXB2) with Creatinine - Aspirin (which inhibits platelet cyclooxygenase) reduces the risk of thrombosis in cardiovascular disease by impairing platelet function. Patients who do not respond to the platelet inhibitory effects of aspirin are designated as "aspirin resistant". The measurement of 11-dhTXB2 in urine (the principal metabolite of platelet cyclooxygenase derived thromboxane B2) may be used in individuals with cardiovascular disease prior to initiation of aspirin therapy, or in individuals non-responsive to aspirin therapy.

The 14-3-3eta protein is a marker of synovial inflammation that is released into synovial fluid and peripheral blood in rheumatoid arthritis (RA) and erosive psoriatic arthritis.

16α-Hydroxyestrone (16α-OH-E1), or hydroxyestrone, also known as estra-1,3,5(10)-trien-3,16α-diol-17-one, is an endogenous steroidal estrogen and a major metabolite of estrone, as well as an intermediate in the biosynthesis of estriol. It is a potent estrogen similarly to estrone, and it has been suggested that the ratio of 16α-hydroxyestrone to 2-OH-E1, the latter being much less estrogenic in comparison and even antiestrogenic in the presence of more potent estrogens like estradiol, may be involved in the pathophysiology of breast cancer. Conversely, 16α-hydroxyestrone may help to protect against osteoporosis.

Percentages of 2-OH-E1, 4-OH-E1, and 16-OH-E1

When evaluating phase I metabolism, it can be helpful to compare the percentages of 2, 4, and 16 OH-E1 metabolites. Most individuals metabolize the majority of their estrogens down the 2-OH-E1 pathway which is generally considered the “safer pathway”. This is followed by 16-OH-E1 and 4-OH-E1 respectively, both of which are deemed more reactive and potentially genotoxic.

In a Hormone Metabolite Assessment Panel (HUMAP) for pre-menopausal women, the percentage of 16-Hydroxyestrone (16-OH-E1) is a critical marker for evaluating estrogen metabolism and its implications for health.

16-OH-E1 is a metabolite of estrogen, produced through the 16α-hydroxylation pathway, and is known for its strong estrogenic properties. In contrast to other estrogen metabolites that are less active, 16-OH-E1 has been linked to an increased risk of estrogen-sensitive conditions, such as certain types of breast and uterine cancers. It promotes the growth of estrogen-responsive tissues and can contribute to conditions associated with estrogen dominance.

16α-Hydroxyestrone (16α-OH-E1), or hydroxyestrone, also known as estra-1,3,5(10)-trien-3,16α-diol-17-one, is an endogenous steroidal estrogen and a major metabolite of estrone, as well as an intermediate in the biosynthesis of estriol. 

16α-Hydroxyestrone (16α-OH-E1), or hydroxyestrone, also known as estra-1,3,5(10)-trien-3,16α-diol-17-one, is an endogenous steroidal estrogen and a major metabolite of estrone, as well as an intermediate in the biosynthesis of estriol. It is a potent estrogen similarly to estrone, and it has been suggested that the ratio of 16α-hydroxyestrone to 2-OH-E1, the latter being much less estrogenic in comparison and even antiestrogenic in the presence of more potent estrogens like estradiol, may be involved in the pathophysiology of breast cancer. Conversely, 16α-hydroxyestrone may help to protect against osteoporosis.

16α-Hydroxyestrone serves as an important indicator of estrogen metabolism pathways in the body. This compound is a metabolite of estrone (E1), formed through the hydroxylation process at the 16th carbon of the steroid structure. The balance of 16α-Hydroxyestrone, relative to other estrogen metabolites, is particularly significant in assessing hormonal health and the risk of estrogen-related disorders.

Elevated levels of this metabolite are often linked to an increased risk of estrogen-sensitive conditions, such as certain types of breast and endometrial cancers. This is because 16α-Hydroxyestrone is a potent estrogen metabolite that can bind to estrogen receptors, potentially stimulating cellular proliferation in estrogen-sensitive tissues.

16α-Hydroxyestrone (16α-OH-E1), or hydroxyestrone, also known as estra-1,3,5(10)-trien-3,16α-diol-17-one, is an endogenous steroidal estrogen and a major metabolite of estrone, as well as an intermediate in the biosynthesis of estriol. It is a potent estrogen similarly to estrone, and it has been suggested that the ratio of 16α-hydroxyestrone to 2-OH-E1, the latter being much less estrogenic in comparison and even antiestrogenic in the presence of more potent estrogens like estradiol, may be involved in the pathophysiology of breast cancer. Conversely, 16α-hydroxyestrone may help to protect against osteoporosis.

16α-Hydroxyestrone (16α-OH-E1), or hydroxyestrone, also known as estra-1,3,5(10)-trien-3,16α-diol-17-one, is an endogenous steroidal estrogen and a major metabolite of estrone, as well as an intermediate in the biosynthesis of estriol. It is a potent estrogen similarly to estrone, and it has been suggested that the ratio of 16α-hydroxyestrone to 2-OH-E1, the latter being much less estrogenic in comparison and even antiestrogenic in the presence of more potent estrogens like estradiol, may be involved in the pathophysiology of breast cancer. Conversely, 16α-hydroxyestrone may help to protect against osteoporosis.

16a-Hydroxyestrone, particularly in the context of a pre-menopausal Hormone Metabolite Assessment Panel (HUMAP), is a significant marker in understanding estrogen metabolism. Estrogens are a group of hormones critical for sexual and reproductive development, primarily in women. In a pre-menopausal woman, the levels and balance of these hormones are crucial for regular menstrual cycles, fertility, and overall health. The HUMAP test assesses various metabolites of estrogen, among other hormones, to provide a comprehensive view of hormonal balance and metabolism.

16a-Hydroxyestrone is one of the metabolites of estrone, a form of estrogen. It's formed in the body through the hydroxylation of estrone at the 16th carbon position. This particular metabolite is known for its strong estrogenic activity. High levels of 16a-Hydroxyestrone are often associated with an increased risk of estrogen-sensitive conditions like certain types of breast cancer and other estrogen-related disorders. This is due to its potential to stimulate estrogen receptor-positive cells more potently than other estrogen metabolites.

16α-Hydroxyestrone (16α-OH-E1), or hydroxyestrone, also known as estra-1,3,5(10)-trien-3,16α-diol-17-one, is an endogenous steroidal estrogen and a major metabolite of estrone, as well as an intermediate in the biosynthesis of estriol. It is a potent estrogen similarly to estrone, and it has been suggested that the ratio of 16α-hydroxyestrone to 2-OH-E1, the latter being much less estrogenic in comparison and even antiestrogenic in the presence of more potent estrogens like estradiol, may be involved in the pathophysiology of breast cancer. Conversely, 16α-hydroxyestrone may help to protect against osteoporosis.